Charles Schwab’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,115
| Closed | -$7.51K | – | 3534 |
|
|
2023
Q4 | $7.51K | Hold |
1,115
| – | – | ﹤0.01% | 3533 |
|
|
2023
Q3 | $10.2K | Hold |
1,115
| – | – | ﹤0.01% | 3563 |
|
|
2023
Q2 | $23.5K | Sell |
1,115
-2,080
| -65% | -$43.9K | ﹤0.01% | 3539 |
|
|
2023
Q1 | $86K | Sell |
3,195
-549
| -15% | -$14.8K | ﹤0.01% | 3273 |
|
|
2022
Q4 | $133K | Buy |
3,744
+126
| +3% | +$4.46K | ﹤0.01% | 3234 |
|
|
2022
Q3 | $818K | Buy |
3,618
+68
| +2% | +$15.4K | ﹤0.01% | 2850 |
|
|
2022
Q2 | $671K | Buy |
3,550
+593
| +20% | +$112K | ﹤0.01% | 2948 |
|
|
2022
Q1 | $737K | Buy |
2,957
+65
| +2% | +$16.2K | ﹤0.01% | 2970 |
|
|
2021
Q4 | $451K | Hold |
2,892
| – | – | ﹤0.01% | 3180 |
|
|
2021
Q3 | $580K | Buy |
2,892
+124
| +4% | +$24.9K | ﹤0.01% | 3094 |
|
|
2021
Q2 | $708K | Buy |
2,768
+204
| +8% | +$52.2K | ﹤0.01% | 3052 |
|
|
2021
Q1 | $681K | Buy |
2,564
+91
| +4% | +$24.2K | ﹤0.01% | 2974 |
|
|
2020
Q4 | $912K | Buy |
2,473
+227
| +10% | +$83.7K | ﹤0.01% | 2805 |
|
|
2020
Q3 | $549K | Buy |
2,246
+189
| +9% | +$46.2K | ﹤0.01% | 2848 |
|
|
2020
Q2 | $593K | Buy |
2,057
+61
| +3% | +$17.6K | ﹤0.01% | 2768 |
|
|
2020
Q1 | $408K | Sell |
1,996
-31
| -2% | -$6.34K | ﹤0.01% | 2777 |
|
|
2019
Q4 | $906K | Buy |
2,027
+248
| +14% | +$111K | ﹤0.01% | 2627 |
|
|
2019
Q3 | $547K | Hold |
1,779
| – | – | ﹤0.01% | 2762 |
|
|
2019
Q2 | $566K | Buy |
+1,779
| New | +$566K | ﹤0.01% | 2750 |
|